The Food and Drug Administration conducted an inspection for drug quality assurance at KP Pharmaceutical Technology in Bloomington on Feb. 13, according to data published on the FDA’s website.
Findings from the final report showed that KP Pharmaceutical Technology was not required to take corrective actions regarding the organization’s operational management.
The FDA conducts routine inspections of workplaces nationwide to assess whether facilities and their products comply with laws and regulations overseen by the agency for public health. These inspection outcomes are released to the public.
The FDA’s website states that the agency’s primary responsibility is to oversee the safety and quality of human and animal drugs, biological products, medical equipment and tobacco products.
Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.
